Pulmonary toxicity following bleomycin use: A single-center experience

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Bleomycin-induced pulmonary toxicity (BIP) is a serious adverse event in cancer patients, occurring in about 10% of cases.
• Early identification and management of BIP are crucial for patient outcomes.

Purpose of the Study:

• To evaluate the incidence, clinical presentation, and outcomes of bleomycin-induced pulmonary toxicity at a tertiary care cancer center.
• To assess the impact of BIP on patients undergoing chemotherapy for Hodgkin disease and germ cell tumors.

Main Methods:

• A retrospective analysis of 22 patients treated with bleomycin-based chemotherapy regimens (ABVD or BEP) between January 1998 and December 2012.
• Inclusion criteria included respiratory symptoms and/or abnormal high-resolution computed tomography (HRCT) findings suggestive of BIP.
• Patient data on demographics, diagnosis, chemotherapy, clinical presentation, HRCT findings, and treatment outcomes were reviewed.

Main Results:

• Of 22 patients, 14 presented with symptoms like cough and dyspnea, with HRCT showing characteristic lung injury patterns.
• Eight patients were asymptomatic, while two experienced fever and pleuritic pain.
• Two patients required mechanical ventilation and unfortunately died due to multiorgan failure, indicating a mortality rate of approximately 9% in this cohort.

Conclusions:

• Bleomycin-induced pulmonary toxicity is a significant concern, contributing to mortality in cancer patients.
• Physicians must maintain vigilance for BIP, especially in patients receiving bleomycin chemotherapy.
• Prompt recognition and appropriate management of BIP can potentially improve patient survival rates.